Live
- From Blueprints to Skylines: The Journey of Hyderabad’s Top Builders
- PM Modi urges Indian diaspora to participate in 'Bharat Ko Janiye' quiz
- Koraput: Four die as truck hits bike
- Odisha begins Mahtab’s 125th birth anniv celebrations
- Bhadrak: Four held for murder of ex-Sarpanch
- National honour for Odia chest specialist
- Sold newborn traced in Raipur
- AIBOC warns of agitation
- 4 held from Gujarat in ‘digital arrest’ case
- 10 held for attack on MLA Himanshu
Dr Reddy's launches drug in US
Dr Reddy's Laboratories Ltd on Friday announced the launch of Trientine Hydrochloride capsules in the US market.
Hyderabad: Dr Reddy's Laboratories Ltd on Friday announced the launch of Trientine Hydrochloride capsules in the US market.
Trientine works by removing copper from the blood. It is used to treat Wilson's disease, a genetic metabolic defect that causes excess copper to build up in the body. In a regulatory filing, Dr Reddy's Laboratories announced the launch of Trientine Hydrochloride capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) capsules approved by the US Food and Drug Administration (USFDA). "We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners," Chief Executive Officer and Head of Dr Reddy's North America Generics Marc Kikuchi said.
The Syprine brand and generic products had US sales of approximately $94.2 million MAT (Moving Annual Total) for the most recent twelve months ending in December 2019, according to IMS Health. Dr Reddy's Trientine Hydrochloride capsules USP, 250 mg are available in 100 count bottles, the filing said.
